The results indicate that F3.olig2 progenitor cells are superior to F3 NSCs in the improvement of EAE symptoms and that the F3.olig2 cells could be a good candidate for cell therapy of demyelinating diseases including MS. This evidence concerns the gene OLIG2 and myeloid sarcoma.